Vol. 299, Issue 3, 967-972, December 2001

Improved Blood-Brain Barrier Penetration and Enhanced Analgesia of an Opioid Peptide by Glycosylation

R. D. Egleton, S. A. Mitchell¹ , J. D. Huber, M. M. Palian, R. Polt and T. P. Davis

Departments of Pharmacology (R.D.E., J.D.H., T.P.D.) and Chemistry (S.A.M., M.M.P., R.P.), University of Arizona, Tucson, Arizona

Neuropeptide pharmaceuticals have potential for the treatment of neurological disorders, but the blood-brain barrier (BBB) limits entry of peptides to the brain. Several strategies to improve brain delivery are currently under investigation, including glycosylation. In this study we investigated the effect of O-linked glycosylation on Ser⁶ of a linear opioid peptide amide Tyr-D-Thr-Gly-Phe-Leu-Ser-NH₂ on metabolic stability, BBB transport, and analgesia. Peptide stability was studied in brain and serum from both rat and mouse by high-performance liquid chromatography. BBB transport properties were investigated by rat in situ perfusion. Tail-flick analgesia studies were performed on male ICR mice, injected i.v. with 100 µg of peptide ligand. Glycosylation of Ser⁶ of the peptide led to a significant increase in enzymatic stability in both serum and brain. Glycosylation significantly increased the BBB permeability of the peptide from a value of 1.0 ± 0.2 µl · min¹ · g¹ to 2.2 ± 0.2 µl · min¹ · g¹ (p < 0.05), without significantly altering the initial volume of distribution. Analgesia studies showed that the glycosylated peptide gave a significantly improved analgesia after i.v. administration compared with nonglycosylated peptide. The improved analgesia profile shown by the glycosylated peptide is due in part to an improvement in bioavailability to the central nervous system. The bioavailability is increased by improving stability and transport into the brain.